RedHill Biopharma (RDHL) Corporate presentation summary

Corporate and financial highlights

• Focuses on U.S. commercialization and development of drugs for GI, infectious diseases, and oncology, with a strong commercial footprint and late-stage pipeline.

• Reported $4.1M net revenues and 60.6% gross margin for H1 2025; cash balance of $3M as of June 30, 2025.

• Secured $4M strategic investment from Cumberland Pharmaceuticals for a 30% stake in the Talicia business and joint commercialization.

• Equity financing capacity of $31.7M as of December 2025.

Commercial operations and partnerships

• U.S. commercial operations strengthened through partnership with Cumberland Pharmaceuticals to accelerate Talicia sales and expand GI sales promotion.

• Talicia is the leading branded H. pylori therapy among U.S. gastroenterologists, launched in the U.S. and UAE, and listed as a first-line option in the 2024 ACG guideline.

• Over 204 million Americans have formulary coverage for Talicia, with preferred status on major commercial and government formularies.

Talicia (omeprazole magnesium, amoxicillin, rifabutin) product profile

• FDA-approved for H. pylori infection in adults, with high eradication rates (>90%) and minimal resistance to component antibiotics.

• Demonstrated superior efficacy and safety in two Phase 3 studies, with 90% eradication in adherent populations and no significant safety signals.

• Protected by patents through 2042 and FDA QIDP designation, providing 8 years of market exclusivity through 2027.